Welcome to BioMarket Group!

The CNS Market Outlook to 2010

Additional Information

Published Date Oct 5, 2005
Special Offer No
Pages 188
PDF Fact Sheet View Fact Sheet for the report The CNS Market Outlook to 2010 in PDF format.
Published on Date No
Format No
Publisher Business Insights
Product Line No
Full Title No

Availability: In stock

$2,875.00

Quick Overview

CNS disorders contribute to as much as 35% of the disease burden in the seven major pharmaceutical markets (US, Japan, France, Germany, Italy, Spain and UK) as measured in terms of daily-adjusted life years.
Request free sample pages from The CNS Market Outlook to 2010

Executive Summary

CNS disorders contribute to as much as 35% of the disease burden in the seven major pharmaceutical markets (US, Japan, France, Germany, Italy, Spain and UK) as measured in terms of daily-adjusted life years. The worldwide patient population with CNS disorders is steadily rising, both in terms of prevalence and in terms of treatment, driven by an aging population, improving diagnostic techniques, increasing physician and patient awareness and a gradual shift away from the social stigma traditionally attached to many psychiatric conditions. The largest CNS indications in terms of prevalence are depression, migraine and pain, with 80m, 79m and 158m sufferers respectively across the seven major pharmaceutical markets. The fastest growing indication in terms of prevalence is Alzheimer’s disease. By 2010 it is forecast that Alzheimer’s disease will afflict 15m patients. In 2004 Parkinson’s disease affected 2m patients across the seven markets, although epidemiological dynamics do not forecast this indication as a major growth area. Schizophrenia affected an estimated 8m patients in 2004, with prevalence forecast to rise to 9m patients by 2010. Growth rates associated with the prevalence of this disease are relatively robust compared to many other indications. Epilepsy is forecast to have relatively static growth in terms of prevalence of the disease, with 6m sufferers forecast to be affected by the disease by 2010.

Request free sample pages from The CNS Market Outlook to 2010

Other selected research from the 'Markets' category:


The increasing importance of CRM in the pharma industry (Technology Focus)
Due to the unique nature of the pharmaceutical industry there are a number of challenges to be overcome in the installation of CRM solutions. Learn More


The Top 10 Generics Companies: Strategic insight, growth opportunities and competitive dynamics in the US and Europe
This report provides insights into the top 10 generic companies strengths, weaknesses, opportunities and threats in the generic pharmaceutical market, allowing you to tailor the best practice strategies of the generic industry`s leading players to your company`s needs. Learn More

Other selected research from the 'Neurological disorders' category:


Adult ADHD - Strattera Grows Up
With the recent medical classification of adult ADHD and potentially twice the number of patients compared to pediatric ADHD, manufacturers are seeking new indications in this expanding and lucrative market. Lilly`s Strattera was the first drug to exploit this, and is forecast to reach blockbuster status by 2006. Consequently, manufacturers will need to differentiate their products from Strattera. Learn More


Alzheimer's Disease: Current Treatment Practices and Opportunities 2010
This report presents the findings of a comprehensive survey of current clinical practices in the treatment of Alzheimer’s Disease (AD). Learn More

Other selected research from the 'Markets' category:


Therapeutic Monoclonal Antibodies Markets
With a unique ability to specifically target diseased cells while leaving healthy cells unaffected, monoclonal antibodies can serve to diagnose and treat a wide range of medical conditions. Learn More


Global Pharmaceuticals
Global Pharmaceuticals industry profile is an essential resource for top-level data and analysis covering the pharmaceuticals industry. Learn More